Omada's Q2 results validate the growth-to-earnings transition, but key risks linger

What happened

Omada Health reported strong Q2 2026 results with 43% revenue growth, margin expansion, and positive adjusted EBITDA, marking a clear step in converting rapid scaling into earnings. The growth is being driven by product expansion in diabetes and hypertension that lifts revenue per member and improves customer lifetime value through multi-program adoption, while channel partnerships with PBMs and health plans reduce customer acquisition costs. However, the company's earlier disclosed concentration risk with Cigna affiliates and unresolved internal control weaknesses remain important overhangs that the new results do not directly address. AI initiatives are credited with enhancing operational efficiency, but without quantified metrics on per-member cost reduction the magnitude of this leverage is still uncertain. The next verifiable catalyst remains the GLP-1 prescribing launch and its adoption metrics, which will be crucial for sustaining premium growth beyond the current product set.

Implication

The strong Q2 reduces the bear-case probability that member growth would falter below 30% and supports the base scenario of >25% revenue growth and adjusted EBITDA near breakeven to modestly positive. However, until Omada discloses the contribution from Cigna affiliates in recent quarters and shows that related-party A/R and deferred revenue have not deteriorated, the single-partner dependency risk keeps a cap on valuation multiple expansion. The positive adjusted EBITDA is encouraging, but it is not yet clear if it is sustainable without one-time items, so investors should focus on free cash flow conversion and working capital quality in upcoming filings. The GLP-1 prescribing rollout planned for 1H26 (now likely recently launched or imminent) is the next major catalyst; adoption metrics will determine whether the platform can command higher ARPU. A prudent approach is to hold existing positions if the stock remains near the attractive entry level of $11.50–12.90, but add only after the audited results and Q2 10-Q confirm controls remediation progress.

Thesis delta

The Q2 results provide direct evidence that Omada's revenue growth is converting into positive adjusted EBITDA, which was a central condition in the prior base scenario. This reduces the probability of the bear case tied to growth deceleration and operating losses, but the concentration risk with Cigna and unresolved material weaknesses in internal controls remain unchanged and continue to warrant a discount. Consequently, the thesis moves from 'potential buy' to a more confident 'potential buy' with a slight upward bias to conviction, pending disclosure of related-party payments and control remediation progress.